Pharmaceuticals

KELUN PHARMA

KELUN PHARMA released FY2026 Q1 earnings on April 28 During-Market (BJT), actual revenue CNY 4.259 B (forecast CNY 4.614 B), actual EPS CNY 0.29 (forecast CNY 0.4223)

KELUN PHARMA to release FY2026 Q1 earnings on April 29 during market hours (BJT), forecast revenue CNY 4.614 B, EPS CNY 0.4223

KELUN PHARMA released FY2025 earnings on April 2 After-Market (BJT), actual revenue CNY 18.51 B (forecast CNY 17.87 B), actual EPS CNY 1.07 (forecast CNY 1.1793)

KELUN PHARMA released FY2025 Q4 earnings on April 2 After-Market (BJT), actual revenue CNY 5.236 B (forecast CNY 4.938 B), actual EPS CNY 0.3213 (forecast CNY 0.2924)

KELUN PHARMA to Release FY2025 Earnings on April 3 After-Market (BJT), Forecast Revenue CNY 17.87 B, EPS CNY 1.1793

KELUN PHARMA released FY2025 Q3 earnings on October 30 During-Market (BJT), actual revenue CNY 4.193 B (forecast CNY 5.3 B), actual EPS CNY 0.123 (forecast CNY 0.4542)

KELUN PHARMA released FY2025 9 Months Earnings on October 30 During-Market (BJT), actual revenue CNY 13.28 B, actual EPS CNY 0.7536

KELUN PHARMA to Release FY2025 Q3 Earnings on October 31 During-Market (BJT), Forecast Revenue CNY 5.3 B, EPS CNY 0.4542

Colenso Pharma Secretary Reveals Ownership of Kelun Biotech and R&D Pipeline Layout

KELUN PHARMA released FY2025 Semi-Annual Earnings on August 28 Pre-Market (BJT), actual revenue CNY 9.083 B, actual EPS CNY 0.63

KELUN PHARMA released FY2025 Q2 earnings on August 28 Pre-Market (BJT), actual revenue CNY 4.693 B (forecast CNY 5.32 B), actual EPS CNY 0.2606 (forecast CNY 0.4692)

KELUN PHARMA to Release FY2025 Semi-Annual Earnings on August 18, 2025 (BJT)

Kueren Pharmaceutical's Credit Rating Rated AAA with Stable Outlook

Kalonji Pharmaceutical Explains Reasons for Lower Dividend Payout Ratio

CEO Liu Genxin Endorses Product at 75 with Bare Chest

JPMorgan Downgrades Kailo Pharmaceutical to Neutral

Colton Pharmaceutical's progress in bispecific antibody drug development

Fund Favorites Sector Experiences Capital Outflow Over 3.1 Billion

Kehl Pharma Announces High Dividends and Supports Subsidiary Financing

Kelin Pharmaceutical Subsidiary Obtains Registration Approval for Cefazolin Sodium Injection

002422

Huilun Pharmaceutical recently submitted a prospectus and plans to list on the Hong Kong Stock Exchange. The revenue for the year 2022 was 690 million, with a net loss of 170 million. The expected revenue for 2023 to 2025 is 985 million, 686 million, and 686 million, respectively. The company's products cover areas such as immune inflammation, pain treatment, and oncology, with an innovative drug pipeline progressing steadily. Dong Dalun and his family hold shares in the company, with Dong Dalun holding 27.04%

雷帝触网

Huilun Pharmaceutical rushes to the Hong Kong stock market: annual revenue of 690 million, net loss of 170 million, many family members of Dong Dalun hold shares

516820

516500

159837

588130

159316

159849

588250

159102

06990

510660

159992

159506

520880

512290

159615

159859

CMB International released a research report, raising the target price for KELUN PHARMA to HKD 507.11, maintaining a "Buy" rating. The report pointed out that KELUN PHARMA's total revenue last year was RMB 2.06 billion, a year-on-year increase of 6.5%. Although the net loss widened to RMB 382 million due to commercialization expansion and clinical advancement, the company is well-capitalized and is expected to have RMB 4.6 billion in cash and financial assets by the end of 2025

AASTOCKS

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Merchants CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

Huaan Hang Seng Biotech ETF

Penghua CSI HK Connect Health Care Composite ETF

SKB BIO

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ICBCCS SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Guotai CSI Bio-medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Southern Hang Seng Biotech ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

Tianhong CNI BIOMEDICINE ETF

Bosera Hang Seng Health Care ETF(QDII)

CITIC International raised the target price of KELUN PHARMA to 507.11 yuan, rating it as "Buy."

Citi released a research report, lowering the target price for KELUN BIO to RMB 500.7, maintaining a "Outperform" rating. The report pointed out that KELUN BIO's revenue grew by 6.5% to RMB 2.058 billion last year, but the net loss widened by 43.2% to RMB 382 million, both exceeding expectations. It is expected that product sales will grow in the second half of 2025, with management anticipating that sac-TMT sales will double and will disclose more clinical trial data. Sales forecasts were lowered by 15.7% and 11.9%, while net profit forecasts were cut by 85.9% and 51.5%

In "The Big Banks," Citigroup lowered the target price for KELUN PHARMA to 500.7 yuan with a rating of "Outperform the Market."

Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. announced its 2025 annual results, reporting revenue of approximately RMB2057.92 million and a gross profit of RMB1478.78 million, with a year-on-year increase. The company recorded a loss of RMB381.97 million, but maintains strong cash reserves of RMB4559.36 million and a declining debt-to-asset ratio of 18.7%. Kelun-Biotech has successfully launched multiple products, including four approved for marketing in China, and is advancing a robust pipeline of over 30 drug candidates, focusing on innovative therapies for unmet medical needs.

prnewswire

22:31 ETKELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF

Kelun-Biotech Sets March 2026 Board Meeting and Webcast for 2025 Results

Tip Ranks

Kelun-Biotech Sets March 2026 Board Meeting and Webcast for 2025 Results

02142

Sichuan Kelun-Biotech and Harbour BioMed announced that the National Medical Products Administration (NMPA) of China has approved their IND application for SKB575/HBM7575, a bispecific antibody for treating atopic dermatitis. This innovative therapy targets thymic stromal lymphopoietin (TSLP) and aims to provide durable disease control with reduced dosing frequency. The approval marks a significant milestone in addressing unmet needs in autoimmune diseases, with both companies optimistic about advancing this treatment through clinical development.

HBM HOLDINGS-B

06:47 ETKelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis

01093

Mainland Chinese investors have increased their investments in Hong Kong-listed drug stocks, with the Hang Seng Southbound Connect Hong Kong Innovative Drug Index rising about 9% recently. CSPC Pharmaceutical Group and Sichuan Kelun-Biotech saw significant gains. Innovent Biologics announced a major collaboration with Eli Lilly worth up to $8.85 billion, enhancing its drug development process. This trend reflects a shift in how Chinese drug makers engage with global partners, as they gain more control over the development of their medicines amid a competitive pharmaceutical landscape.

KELUN PHARMA(002422.SZ)

Huilun Pharmaceutical rushes to the Hong Kong stock market: annual revenue of 690 million, net loss of 170 million, many family members of Dong Dalun hold shares

CITIC International raised the target price of KELUN PHARMA to 507.11 yuan, rating it as "Buy."

In "The Big Banks," Citigroup lowered the target price for KELUN PHARMA to 500.7 yuan with a rating of "Outperform the Market."

22:31 ETKELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF

Kelun-Biotech Sets March 2026 Board Meeting and Webcast for 2025 Results

06:47 ETKelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis

Mainland China’s investors pour into Hong Kong-listed drug stocks